about
A case report of multiple primary prostate tumors with differential drug sensitivityDual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advancesPutting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-TDefining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforcePembrolizumab: patient selection or immune intensification?Radium-223 mechanism of action: implications for use in treatment combinationsNeoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerInsights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19The Role of Lineage Plasticity in Prostate Cancer Therapy ResistancePhase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinomaPhase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsProduct review: avelumab, an anti-PD-L1 antibody
P50
Q89701424-50BA9D21-4A3C-4AD9-BB3F-7B8333B5B203Q89807818-50262701-C4CA-44FD-9EB6-72679E4911AAQ90125986-83DE21C0-2CD2-4F0A-BD38-2D99FDC26D6AQ90833376-EA4B340E-E128-419C-94BA-FB5795C259A5Q91069753-AA6DF0B2-FE72-4016-8D55-C90DE0C36C2BQ91236176-75470D2D-4FD9-46F7-ADB4-99CBBB2E2A32Q91738343-BFD96543-D429-4739-A665-243D44A8BF57Q91998907-49E31B76-B4F4-47C6-9AAA-D4CA14DBE83FQ92295261-FC4D75B9-B3EA-4A72-AB4B-1B277AF40EA5Q92919990-9D2990F0-73FD-4391-9FE2-F7283113D96AQ93129617-BE78EDB8-DC20-465D-8BB5-ECC07F7B9453Q93338919-368E80CA-42C6-4D73-A4DA-E3B6C17DC5E1
P50
description
researcher
@en
wetenschapper
@nl
name
James L Gulley
@en
James L Gulley
@nl
type
label
James L Gulley
@en
James L Gulley
@nl
prefLabel
James L Gulley
@en
James L Gulley
@nl
P31
P496
0000-0002-6569-2912